Human research · RCT
da Costa Pinaffi-Langley AC et al., JAMA Network Open 2026
In a 4-week double-blind, placebo-controlled trial in 50 middle-aged adults with obesity, urolithin A 1000 mg/day did NOT improve the primary outcome (brachial artery flow-mediated dilation) or any secondary peripheral endothelial measure. A secondary brain measure (fNIRS task-evoked prefrontal oxygenation response during a working-memory task) increased versus placebo, with no change in cognitive task performance. Null primary; the brain signal is a secondary surrogate finding needing replication.
Source: Urolithin A and Endothelial and Cerebrovascular Function in Middle-Aged Adults With Obesity: A Randomized Clinical Trial. da Costa Pinaffi-Langley AC, Gulej R, Kaposzta Z, et al. JAMA Network Open. 2026;9(10):e2638047. doi:10.1001/jamanetworkopen.2026.38047. PMID:42853569; PMC13653284. Published 2026-10-09. Registry: ClinicalTrials.gov NCT05921266
Verified research card EL-20261018-01